Ayala Pharmaceuticals Inc (fka ADXS)

[hebbeke47]

Maybe they want to put some pressure on a partner.
Clinical trials keeps running and a partner could do a MAA with the Europeanen Union again ?

The Company continues to believe that the results from the GOG-0265 study are clinically meaningful and provide proof-of-concept that axalimogene filolisbac demonstrated clinical activity in metastatic cervical cancer. The withdrawal of this application does not impact the ongoing clinical trials of axalimogene filolisbac. As previously communicated, Advaxis is actively seeking a partner to support the late-stage cervical cancer program.